Fifth Third Bancorp Boosts Stake in Hims & Hers Health, Inc. $HIMS

Fifth Third Bancorp increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3,584.8% during the first quarter, Holdings Channel.com reports. The fund owned 82,171 shares of the company’s stock after buying an additional 79,941 shares during the period. Fifth Third Bancorp’s holdings in Hims & Hers Health were worth $1,706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Binnacle Investments Inc acquired a new position in Hims & Hers Health in the 3rd quarter worth about $28,000. Silicon Valley Capital Partners purchased a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $48,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Bogart Wealth LLC raised its stake in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Citigroup raised their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. TD Cowen lowered their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Bank of America increased their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $30.70.

Hims & Hers Health Trading Down 3.2%

Shares of Hims & Hers Health stock opened at $31.69 on Thursday. The stock has a market cap of $7.34 billion, a P/E ratio of -352.12, a P/E/G ratio of 92.11 and a beta of 2.35. The stock’s 50 day simple moving average is $30.52 and its 200-day simple moving average is $26.34. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 EPS. Analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Irene Becklund sold 7,573 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total transaction of $229,083.25. Following the transaction, the insider directly owned 11,280 shares in the company, valued at $341,220. This trade represents a 40.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 83,126 shares of company stock worth $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.